• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Catheter Precision Inc.

    11/13/24 11:14:58 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care
    Get the next $VTAK alert in real time by email
    SC 13G/A 1 ea022071814-13ga1intra_cathe.htm AMENDMENT NO. 1 TO SCHEDULE 13G

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 1)*

     

    Catheter Precision, Inc.

     

    (Name of Issuer)

     

    Common stock, par value $0.0001 per share

     

    (Title of Class of Securities)

     

    74933X609

    (CUSIP Number)

     

    September 30, 2024

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    a.☐ Rule 13d-1(b)
    b.☒ Rule 13d-1(c)
    c.☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    Page 1 of 6

     

     

    CUSIP No. 74933X609

     

    1. Names of Reporting Persons.

    Mitchell P. Kopin
    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐
    (b)
    ☐
    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

     

    United States of America
    Number of
    Shares Beneficially
    Owned by Each
    Reporting
    Person With:
    5. 

    Sole Voting Power

     

    0
    6.

    Shared Voting Power

     

    181,336
    7.

    Sole Dispositive Power

     

    0
    8.

    Shared Dispositive Power

     

    181,336
    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

     

    181,336 (see Item 4)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐

     

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

     

    4.99% (see Item 4)

    12. Type of Reporting Person (See Instructions)

    IN; HC

     

    Page 2 of 6

     

     

    CUSIP No. 74933X609

     

    1. Names of Reporting Persons.

    Daniel B. Asher
    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐
    (b)
    ☐
    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

     

    United States of America
    Number of
    Shares Beneficially
    Owned by Each
    Reporting
    Person With:
    5. 

    Sole Voting Power

     

    0
    6.

    Shared Voting Power

     

    181,336
    7.

    Sole Dispositive Power

     

    0
    8.

    Shared Dispositive Power

     

    181,336
    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

     

    181,336 (see Item 4)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐

     

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

     

    4.99% (see Item 4)

    12. Type of Reporting Person (See Instructions)

    IN; HC

     

    Page 3 of 6

     

     

    CUSIP No. 74933X609

     

    1. Names of Reporting Persons.

    Intracoastal Capital LLC
    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐
    (b)
    ☐
    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

     

    Delaware
    Number of
    Shares Beneficially
    Owned by Each
    Reporting
    Person With:
    5. 

    Sole Voting Power

     

    0
    6.

    Shared Voting Power

     

    181,336
    7.

    Sole Dispositive Power

     

    0
    8.

    Shared Dispositive Power

     

    181,336
    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

     

    181,336 (see Item 4)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐

     

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

     

    4.99% (see Item 4)

    12. Type of Reporting Person (See Instructions)

    OO

     

    Page 4 of 6

     

     

    This Amendment No. 1 is being filed jointly by the Reporting Persons and amends the Schedule 13G initially filed by the Reporting Persons with the Securities and Exchange Commission (the “SEC”) on September 12, 2024 (the “Schedule 13G”).

     

    Except as set forth below, all Items of the Schedule 13G remain unchanged. All capitalized terms not otherwise defined herein shall have the meanings ascribed to such terms in the Schedule 13G.

     

    Item 4.Ownership.

     

    (a) and (b):

     

    As of the close of business on September 30, 2024, each of the Reporting Persons may have been deemed to have beneficial ownership of 181,336 shares of Common Stock, which consisted of (i) 194 shares of Common Stock issuable upon exercise of a warrant held by Intracoastal (“Intracoastal Warrant 1”), (ii) 111 shares of Common Stock issuable upon exercise of a second warrant held by Intracoastal (“Intracoastal Warrant 2”) and (iii) 181,031 shares of Common Stock issuable upon exercise of a third warrant held by Intracoastal (“Intracoastal Warrant 3”), and all such shares of Common Stock in the aggregate represent beneficial ownership of approximately 4.99% of the Common Stock, based on (1) 3,452,652 shares of Common Stock outstanding as of September 30, 2024, as reported to the Reporting Persons by the Issuer, plus (2) 194 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1, (3) 111 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2 and (4) 181,031 shares of Common Stock issuable upon exercise of Intracoastal Warrant 3. The foregoing excludes (I) 318,969 shares of Common Stock issuable upon exercise of Intracoastal Warrant 3 because Intracoastal Warrant 3 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 3 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock, (II) 500,000 shares of Common Stock issuable upon exercise of a fourth warrant held by (“Intracoastal Warrant 4”) because Intracoastal Warrant 4 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 4 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock, (III) 500,000 shares of Common Stock issuable upon exercise of a fifth warrant held by (“Intracoastal Warrant 5”) because Intracoastal Warrant 5 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 5 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock, (IV) 1,650 shares of Common Stock issuable upon exercise of a sixth warrant held by (“Intracoastal Warrant 6”) because Intracoastal Warrant 6 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 6 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock and (V) 1,650 shares of Common Stock issuable upon exercise of a seventh warrant held by (“Intracoastal Warrant 7”) because Intracoastal Warrant 7 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 7 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock. Without such blocker provisions, each of the Reporting Persons may have been deemed to have beneficial ownership of 1,503,605 shares of Common Stock.

      

    (c)Number of shares as to which each Reporting Person has:

     

    (i)Sole power to vote or to direct the vote:       0     .

     

    (ii)Shared power to vote or to direct the vote:      181,336      .

     

    (iii)Sole power to dispose or to direct the disposition of      0     .

     

    (iv)Shared power to dispose or to direct the disposition of      181,336     .

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following þ.

     

    Item 10.Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

    Page 5 of 6

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: November 13, 2024

     

      /s/ Mitchell P. Kopin
      Mitchell P. Kopin
       
      /s/ Daniel B. Asher
      Daniel B. Asher

     

      Intracoastal Capital LLC
         
      By: /s/ Mitchell P. Kopin
        Mitchell P. Kopin, Manager

     

    Page 6 of 6

     

    Get the next $VTAK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VTAK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VTAK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Caruso James Joseph converted options into 41 shares, increasing direct ownership by 456% to 50 units (SEC Form 4)

    4 - Catheter Precision, Inc. (0001716621) (Issuer)

    12/8/25 4:54:19 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Chairman of the Board and CEO Jenkins David A converted options into 43,006 shares, increasing direct ownership by 695% to 13,799 units (SEC Form 4)

    4 - Catheter Precision, Inc. (0001716621) (Issuer)

    12/8/25 4:45:07 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Arno Andrew

    4 - Catheter Precision, Inc. (0001716621) (Issuer)

    8/14/25 4:34:48 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    $VTAK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Catheter Precision Secures Tender From Leading Hospital in Hungary

    FORT MILL, S.C., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK), a leading U.S.-based medical device company focusing on advanced solutions in the cardiac electrophysiology market, is proud to announce that its VIVO™ system has successfully secured a significant tender at Albert Szent-Györgyi Health Centre (Szeged University Hospital) in Hungary. This achievement marks Catheter Precision's inaugural installation in Hungary and reinforces its commitment to growth across Central and Eastern Europe. The tender was awarded in partnership with Fototronic, a well-established local distributor. Installation of the VIVO system is anticipated in the first quarter of 2026.

    12/3/25 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Catheter Precision (VTAK) Reports Third Quarter and First Nine Months 2025 Results of Operations

    FORT MILL, S.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company focused on the cardiac electrophysiology marketplace, today reported its results of operations for the quarter and nine months ended September 30, 2025. Highlights of the quarter and nine months include: Financial Highlights Total revenue reported for Q3 2025 was $226,000, an increase of 135% compared with $96,000 in Q3 2024.Total revenue was $581,000 for the nine months ended September 30, 2025, compared with $271,000 for the nine months ended September 30, 2024, an increase of 114%.GAAP net loss for Q3 2025 was $2,251,000, a 45% reduction compared to $

    11/13/25 4:15:00 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Catheter Precision, Inc. Comments on Recent Market Activity

    FORT MILL, S.C., June 12, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, is issuing this press release in response to recent increases in trading activity in its common stock. The Company is not aware of any information related to the Company or its operations that it would have expected to cause increased market activity. The Company continues to pursue its strategic plans as previously disclosed, including its ongoing efforts to secure financing to meet its liquidity needs. CONTACTS: At the CompanyDavid [email protected] # # #

    6/12/25 2:14:04 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    $VTAK
    SEC Filings

    View All

    Catheter Precision Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement

    8-K - Catheter Precision, Inc. (0001716621) (Filer)

    11/21/25 4:15:57 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Catheter Precision Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Catheter Precision, Inc. (0001716621) (Filer)

    11/14/25 5:20:52 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Catheter Precision Inc.

    10-Q - Catheter Precision, Inc. (0001716621) (Filer)

    11/13/25 4:16:52 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    $VTAK
    Leadership Updates

    Live Leadership Updates

    View All

    Catheter Precision, Inc. Announces New Chief Financial Officer

    FORT MILL, SC / ACCESSWIRE / January 7, 2025 / Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced that it has brought on board Philip Anderson, to take on the position of Chief Financial Officer. Margrit Thomassen, who has been our Interim Chief Financial Officer, will continue with the company in the role of Controller.David Jenkins, CEO of Catheter Precision, commented on the hire, "After some time of searching for the right fit, we are happy to have concluded our search with Phil Anderson joining the team. His background includes executive management across a variety of industries, managing hedge fund

    1/7/25 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Catheter Precision, Inc. (NYSE American:VTAK) Presenting at the Sequire Investor Summit in Puerto Rico

    FORT MILL, SC / ACCESSWIRE / January 22, 2024 / Catheter Precision, Inc. (NYSE:VTAK), (the Company) a pioneering U.S. based medical device company committed to enhancing the well-being of patients with cardiac arrhythmias, is pleased to declare its participation in the forthcoming Sequire Investor Summit 2024. The eagerly awaited event, slated for January 23-25, 2024, at the Condado Vanderbilt Hotel in San Juan, Puerto Rico, is poised to provide a spectrum of compelling opportunities for funds, companies, and investors.Puerto Rico has become a hub for family offices, funds, and affluent investors, thanks to its advantageous tax benefits. It stands out as one of the rare locations globally wh

    1/22/24 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    $VTAK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Catheter Precision Inc.

    SC 13G/A - Catheter Precision, Inc. (0001716621) (Subject)

    11/14/24 5:12:56 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Catheter Precision Inc.

    SC 13G/A - Catheter Precision, Inc. (0001716621) (Subject)

    11/13/24 11:14:58 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by Catheter Precision Inc.

    SC 13D/A - Catheter Precision, Inc. (0001716621) (Subject)

    10/30/24 5:26:20 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    $VTAK
    Financials

    Live finance-specific insights

    View All

    Catheter Precision, Inc. Announces First Quarter 2025 Update and Financial Results

    FORT MILL, S.C., May 14, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the period ending March 31, 2025. Highlights of the first quarter include: Commercial Endeavors Approximately 50 hospitals are currently in the process of evaluating either VIVO, LockeT or both devices demonstrating that our new sales team continues to build a strong pipeline.After the close of the March quarter, the Company announced its acquisition of the assets of Cardionomics, Inc. through its newly formed, 82% owned subsidiary, Cardionomix, Inc. Th

    5/14/25 4:30:00 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Catheter Precision, Inc. Announces Fourth Quarter and Full Year 2024 Update and Financial Results

    FORT MILL, S.C., March 28, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the period ending December 31, 2024. Highlights of 2024 and the fourth quarter include: New Chief Commercial Officer (CCO) joined in Q2, 2024.Replaced the majority of our prior sales team with new salespeople selected by our new CCO and our CEO. Training was completed in Q3, 2024.The first sales of LockeT occurred in Q2 2024 and grew sequentially each quarter through the end of the year, to both new and repeat customers.The number of hospitals, inclu

    3/28/25 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Catheter Precision, Inc. Announces Third Quarter Update and Financial Results

    FORT MILL, SC / ACCESSWIRE / November 13, 2024 / Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the period ending September 30, 2024.Highlights of the third quarter include:Commercial EndeavorsMarie-Claude Jaques, our new Chief Commercial Officer, has now completed her first full quarter of engagement with the company, along with many of the new sales and clinical persons brought on board midway through the second quarter.The company now has 87 hospitals, including ambulatory surgical centers, in its pipeline of potential customers who have expressed i

    11/13/24 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care